中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

32 records (took 0.044 seconds)

    N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
    2.
    发明授权
    N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators 失效
    N-（2-苄基）-2-苯基丁酰胺作为雄激素受体调节剂

    公开(公告)号：US07763659B2

    公开(公告)日：2010-07-27

    申请号：US11712727

    申请日：2007-03-01

    Applicant: Barbara Hanney ,  Yuntae Kim ,  Michael R. Krout ,  Robert S. Meissner ,  Helen J. Mitchell ,  Jeffrey Musselman ,  James J. Perkins ,  Jiabing Wang

    Inventor： Barbara Hanney ,  Yuntae Kim ,  Michael R. Krout ,  Robert S. Meissner ,  Helen J. Mitchell ,  Jeffrey Musselman ,  James J. Perkins ,  Jiabing Wang

    IPC: A61K31/165

    CPC classification number: C07D295/205 ,  C07C233/13 ,  C07C235/34 ,  C07C255/60 ,  C07C271/12 ,  C07C271/22 ,  C07C2601/02 ,  C07D213/61 ,  C07D213/73

    Abstract: Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

    Abstract translation: 结构式I的化合物是以组织选择性方式的雄激素受体（AR）的调节剂。 这些化合物可用于增强弱化肌张力和治疗由雄激素缺乏引起的疾病或可由雄激素给药改善的疾病，包括骨质疏松症，骨质减少，糖皮质激素诱导的骨质疏松症，牙周病，骨折，骨重建后的骨损伤 手术，肌营养不良，虚弱，老化的皮肤，男性性腺机能减退，女性绝经后症状，动脉粥样硬化，高胆固醇血症，高脂血症，肥胖，再生障碍性贫血和其他造血障碍，炎性关节炎和关节修复，艾滋病毒消耗，前列腺癌，良性前列腺增生 ），腹部肥胖，代谢综合征，II型糖尿病，癌症恶病质，阿尔茨海默氏病，肌营养不良症，认知衰退，性功能障碍，睡眠呼吸暂停，抑郁症，卵巢早衰以及自身免疫性疾病，单独或与其它活性剂组合。

    2-HYDROXY-2-PHENYLTHIOPHENYLPROPIONAMIDES AS ANDROGEN RECEPTOR MODULATORS
    3.
    发明申请
    2-HYDROXY-2-PHENYLTHIOPHENYLPROPIONAMIDES AS ANDROGEN RECEPTOR MODULATORS 审中-公开
    2-羟基-2-苯乙烯基戊二酸作为雄激素受体调节剂

    公开(公告)号：US20090275515A1

    公开(公告)日：2009-11-05

    申请号：US12442581

    申请日：2007-10-15

    Applicant: Yuntae Kim ,  Robert S. Meissner ,  Helen J. Mitchell ,  James J. Perkins ,  Michael A. Rossi ,  Jiabing Wang

    Inventor： Yuntae Kim ,  Robert S. Meissner ,  Helen J. Mitchell ,  James J. Perkins ,  Michael A. Rossi ,  Jiabing Wang

    IPC: A61K31/44 ,  C07D213/56 ,  C07D409/12 ,  C07D401/12 ,  A61K31/4365 ,  A61K31/437 ,  A61P19/00 ,  A61K31/565 ,  A61K38/29 ,  A61K38/27 ,  A61K31/59 ,  A61P35/00

    CPC classification number: C07D213/40 ,  C07D409/12

    Abstract: Compounds of structural formula (I) are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HFV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

    Abstract translation: 结构式（I）的化合物是以组织选择性方式的雄激素受体（AR）的调节剂。 这些化合物可用于增强弱化肌张力和治疗由雄激素缺乏引起的疾病或可由雄激素给药改善的疾病，包括骨质疏松症，骨质减少，糖皮质激素诱导的骨质疏松症，牙周病，骨折，骨重建后的骨损伤 手术，肌肉减少症，虚弱，衰老皮肤，男性性腺机能减退，女性绝经后症状，动脉粥样硬化，高胆固醇血症，高脂血症，肥胖，再生障碍性贫血和其他造血障碍，炎性关节炎和关节修复，HFV消耗，前列腺癌，良性前列腺增生 ），腹部肥胖，代谢综合征，II型糖尿病，癌症恶病质，阿尔茨海默氏病，肌营养不良症，认知衰退，性功能障碍，睡眠呼吸暂停，抑郁症，卵巢早衰以及自身免疫性疾病，单独或与其它活性剂组合。

    Fluorinated 4-azasteroid derivatives as androgen receptor modulators
    4.
    发明申请
    Fluorinated 4-azasteroid derivatives as androgen receptor modulators 失效

    公开(公告)号：US20090082320A1

    公开(公告)日：2009-03-26

    申请号：US12313166

    申请日：2008-11-18

    Applicant: Robert S. Meissner ,  James J. Perkins

    Inventor： Robert S. Meissner ,  James J. Perkins

    IPC: A61K31/58

    CPC classification number: C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04

    Abstract: Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and/or muscle tissue while antagonizing the AR in the prostate of a male patient or in the uterus of a female patient. These compounds are therefore useful in the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, cancer cachexia, muscular dystrophies, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

    N-(2-Benzyl)-2-Phenylbutanamides As Androgen Receptor Modulators
    5.
    发明申请
    N-(2-Benzyl)-2-Phenylbutanamides As Androgen Receptor Modulators 失效
    N-（2-苄基）-2-苯基丁酰胺作为雄激素受体调节剂

    公开(公告)号：US20080139630A1

    公开(公告)日：2008-06-12

    申请号：US11628685

    申请日：2005-06-03

    Applicant: Barbara Hanney ,  Yuntae Kim ,  Michael R. Krout ,  Robert S. Meissner ,  Helen J. Mitchell ,  Jeffrey Musselman ,  James J. Perkins ,  Jiabing Wang

    Inventor： Barbara Hanney ,  Yuntae Kim ,  Michael R. Krout ,  Robert S. Meissner ,  Helen J. Mitchell ,  Jeffrey Musselman ,  James J. Perkins ,  Jiabing Wang

    IPC: A61K31/44 ,  A61P35/00 ,  C07C233/00 ,  C07D211/80 ,  A61K31/165

    CPC classification number: C07D295/205 ,  C07C233/13 ,  C07C235/34 ,  C07C255/60 ,  C07C271/12 ,  C07C271/22 ,  C07C2601/02 ,  C07D213/61 ,  C07D213/73

    Abstract: Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

    Abstract translation: 结构式I的化合物是以组织选择性方式的雄激素受体（AR）的调节剂。 这些化合物可用于增强减弱的肌肉紧张度和治疗由雄激素缺乏引起的或由雄激素施用引起的疾病的治疗，包括骨质疏松症，骨质减少症，糖皮质激素诱导的骨质疏松症，牙周病骨折，骨重建手术后的骨损伤 ，肌肉减少症，虚弱，老化的皮肤，男性性腺机能减退，妇女绝经后症状，动脉粥样硬化，高胆固醇血症，高脂血症，肥胖，再生障碍性贫血和其他造血障碍，炎症性关节炎和关节修复，艾滋病毒消耗，前列腺癌，良性前列腺增生症（BPH） ，腹部肥胖，代谢综合征，II型糖尿病，癌症恶病质，阿尔茨海默病，肌营养不良症，认知衰退，性功能障碍，睡眠呼吸暂停，抑郁症，卵巢早衰，以及自身免疫疾病，单独或与其他活性剂组合。

    N-(Pyridin-4-Yl)-2-Phenylbutanamides as Androgen Receptor Modulators
    8.
    发明申请
    N-(Pyridin-4-Yl)-2-Phenylbutanamides as Androgen Receptor Modulators 审中-公开
    N-（吡啶-4-基）-2-苯基丁酰胺作为雄激素受体调节剂

    公开(公告)号：US20090088458A1

    公开(公告)日：2009-04-02

    申请号：US11989412

    申请日：2006-07-28

    Applicant: Robert S. Meissner ,  James J. Perkins ,  Yuntae Kim ,  Barbara Hanney ,  Carol A. McVean

    Inventor： Robert S. Meissner ,  James J. Perkins ,  Yuntae Kim ,  Barbara Hanney ,  Carol A. McVean

    IPC: A61K31/4418 ,  C07D213/36 ,  A61P19/02 ,  A61K38/27 ,  C07D213/63

    CPC classification number: C07D213/61 ,  A61K31/44 ,  C07D213/64 ,  C07D213/65 ,  Y02A50/401

    Abstract: Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

    Abstract translation: 结构式I的化合物是以组织选择性方式的雄激素受体（AR）的调节剂。 这些化合物可用于增强弱化肌张力和治疗由雄激素缺乏引起的疾病或可由雄激素给药改善的疾病，包括骨质疏松症，骨质减少，糖皮质激素诱导的骨质疏松症，牙周病，骨折，骨重建后的骨损伤 手术，肌营养不良，虚弱，老化的皮肤，男性性腺机能减退，女性绝经后症状，动脉粥样硬化，高胆固醇血症，高脂血症，肥胖，再生障碍性贫血和其他造血障碍，炎性关节炎和关节修复，艾滋病毒消耗，前列腺癌，良性前列腺增生 ），腹部肥胖，代谢综合征，II型糖尿病，癌症恶病质，阿尔茨海默氏病，肌营养不良症，认知衰退，性功能障碍，睡眠呼吸暂停，抑郁症，卵巢早衰以及自身免疫性疾病，单独或与其它活性剂组合。

    N-(Pyridin-3-Yl)-2-Phenylbutanamides As Androgen Receptor Modulators
    9.
    发明申请
    N-(Pyridin-3-Yl)-2-Phenylbutanamides As Androgen Receptor Modulators 审中-公开
    N-（吡啶-3-基）-2-苯基丁酰胺作为雄激素受体调节剂

    公开(公告)号：US20080124402A1

    公开(公告)日：2008-05-29

    申请号：US11666525

    申请日：2005-10-25

    Applicant: Yuntae Kim ,  Joshua Close ,  Mark E. Duggan ,  Barbara Hanney ,  Robert S. Meissner ,  Jeffrey Musselman ,  James J. Perkins ,  Jiabing Wang

    Inventor： Yuntae Kim ,  Joshua Close ,  Mark E. Duggan ,  Barbara Hanney ,  Robert S. Meissner ,  Jeffrey Musselman ,  James J. Perkins ,  Jiabing Wang

    IPC: A61K33/16 ,  C07D213/02 ,  A61K31/44 ,  A61K31/56 ,  A61K38/16 ,  A61K31/59 ,  A61P19/10 ,  A61P19/08 ,  A61K31/66 ,  A61K31/4535 ,  A61K33/10 ,  A61K33/06

    CPC classification number: C07D213/64 ,  A61K31/44 ,  C07D213/74

    Abstract: Compounds of structural formula (I) are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

    Abstract translation: 结构式（I）的化合物是以组织选择性方式的雄激素受体（AR）的调节剂。 这些化合物可用于增强弱化肌张力和治疗由雄激素缺乏引起的疾病或可由雄激素给药改善的疾病，包括骨质疏松症，骨质减少，糖皮质激素诱导的骨质疏松症，牙周病，骨折，骨重建后的骨损伤 手术，肌营养不良，虚弱，老化的皮肤，男性性腺机能减退，女性绝经后症状，动脉粥样硬化，高胆固醇血症，高脂血症，肥胖，再生障碍性贫血和其他造血障碍，炎性关节炎和关节修复，艾滋病毒消耗，前列腺癌，良性前列腺增生 ），腹部肥胖，代谢综合征，II型糖尿病，癌症恶病质，阿尔茨海默氏病，肌营养不良症，认知衰退，性功能障碍，睡眠呼吸暂停，抑郁症，卵巢早衰以及自身免疫性疾病，单独或与其它活性剂组合。

    Fluorinated 4-azasteroid derivatives as androgen receptor modulators
    10.
    发明授权
    Fluorinated 4-azasteroid derivatives as androgen receptor modulators 失效
    氟化4-氮杂甾体衍生物作为雄激素受体调节剂

    公开(公告)号：US07186838B2

    公开(公告)日：2007-03-06

    申请号：US10507239

    申请日：2003-03-07

    Applicant: Robert S. Meissner ,  James J. Perkins

    Inventor： Robert S. Meissner ,  James J. Perkins

    IPC: C07D221/18 ,  C07D401/12

    CPC classification number: A61K31/473 ,  C07J73/005

    Abstract: Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and/or muscle tissue while antagonizing the AR in the prostate of a male patient or in the uterus of a female patient. These compounds are therefore useful in the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, cancer cachexia, muscular dystrophies, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

    Abstract translation: 结构式I的化合物是以组织选择性方式的雄激素受体（AR）的调节剂。 它们可用作骨和/或肌肉组织中雄激素受体的激动剂，同时拮抗男性患者的前列腺中或在女性患者的子宫中的AR。 因此，这些化合物可用于治疗由雄激素缺乏引起的或可通过雄激素给药改善的病症，包括骨质疏松症，骨质减少症，糖皮质激素诱导的骨质疏松症，牙周病，骨折，骨重建手术后的骨损伤，肌营养不良，虚弱， 老化皮肤，男性性腺机能减退，女性绝经后症状，动脉粥样硬化，高胆固醇血症，高脂血症，肥胖，再生障碍性贫血和其他造血障碍，炎症性关节炎和关节修复，艾滋病毒消耗，前列腺癌，癌症恶病质，肌营养不良，卵巢早衰，及 自身免疫疾病，单独或与其他活性剂组合。

Patent Agency Ranking